Predict your next investment

Corporation
HEALTHCARE | Drug Development
debiopharm.com

See what CB Insights has to offer

Investments

12

Portfolio Exits

2

Partners & Customers

10

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It in-licenses promising biologics and small molecule candidates. The group develops its products with a view to licensing them out to pharmaceutical partners for sales and marketing.

Debiopharm Group Headquarter Location

Chemin Messidor 5-7 Case postale 5911

CH 1002,

Switzerland

+41 (0) 21 321 0111

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Debiopharm Group Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Debiopharm Group Rank

Latest Debiopharm Group News

Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award

Oct 4, 2021

Intellasia East Asia News 04-Oct-2021 Intellasia | PR Newswire Asia | 2:00 PM LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology research projects in 2 categories: Innovative and/or Disruptive Research – Dr. Shumpei Ishikawa and Translational Research – Dr. Hiromichi Ebi. The winners were honored with trophies and a monetary prize during the hybrid (virtual/live) meeting of the 80th Annual Meeting of the Japanese Cancer Association (JCA) on Saturday, October 2nd in Yokohama, Japan by Prof. Hideyuki Saya President of the JCA and Dr. Takato Noumi, Debiopharm's representative in Japan along with Thierry Mauvernay, President of Debiopharm, Bertrand Ducrey CEO of Debiopharm who joined virtually. "Japan and Switzerland share several common values such as commitment to excellence and professional diligence. That's one of the reasons why I believe Japanese research continues to excel and surpass our expectations," expressed Thierry Mauvernay, president of Debiopharm. "It is our honor to award these two new JCA Mauvernay Award winners and realize what their early research could mean for patients in the future through further development." "We were impressed with the potential implications of Dr.Ishikawa and Dr. Ebi in different cancer types. Cancer remains the leading cause of death worldwide so it deserves the deep exploration by great minds in order to come closer to a cure. Japanese cancer researchers continue to capture the attention of the international community as seen in several of the past Nobel Prizes in Medicine. So, we are very pleased to continue to this important award and hope to spark further collaboration," explained Bertrand Ducrey, CEO of Debiopharm. Dr. Shumpei Ishikawa's disruptive research at the University of Toyko, is offering new insights into an aggressive form of gastric cancer, diffuse-type gastric carcinoma (DGC), by exploring the genomic characterization the cancer's life cycle. His comprehensive characterization of DGC includes the identification of genes that drive the transformation of cells to cancer cells (oncogenes), the molecular and cellular dissection of the tumor microenvironment and the environmental factors contributing to the disease. This holistic approach has led to several influential discoveries that have been published in top-ranking scientific journals. Dr. Hiromichi Ebi's translational research at the Aichi Cancer Center Research Institute is examining the development of targeted therapies against tumor with aberrant MAPK signaling. His work is focusing on the elucidation of the molecular mechanisms underlying the differential clinical activities of drugs targeting mutated oncogenes depending on the cancerous tissue and the tumor microenvironment. The JCA-Mauvernay Award Since 2005, the Japanese Cancer Association (JCA) and Debiopharm Group have co-organized the 'JCA-Mauvernay Award'. This prize illustrates the curiosity that drives researchers as well as the scientific cooperation between Japan and Switzerland. It aims at recognizing outstanding achievements in the field of oncology amongst Japanese researchers, in both the fundamental and the clinical aspects. The award has a total value of CHF 25'000. Debiopharm's commitment to patients Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit www.debiopharm.com We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews Debiopharm Contact

Debiopharm Group Investments

12 Investments

Debiopharm Group has made 12 investments. Their latest investment was in VivoSense as part of their Series A on March 3, 2022.

CBI Logo

Debiopharm Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/9/2022

Series A

VivoSense

$25M

Yes

5

2/15/2018

Series A

ABAC Therapeutics

$19.99M

Yes

3

1/13/2015

Series A

GenePOC

Yes

3

11/5/2013

Series E

Subscribe to see more

$99M

Subscribe to see more

10

6/7/2013

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/9/2022

2/15/2018

1/13/2015

11/5/2013

6/7/2013

Round

Series A

Series A

Series A

Series E

Series B - II

Company

VivoSense

ABAC Therapeutics

GenePOC

Subscribe to see more

Subscribe to see more

Amount

$25M

$19.99M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

3

3

10

10

Debiopharm Group Portfolio Exits

2 Portfolio Exits

Debiopharm Group has 2 portfolio exits. Their latest portfolio exit was ABAC Therapeutics on November 21, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/21/2019

Acquired

1

4/27/2015

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/21/2019

4/27/2015

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

Acquirer

Subscribe to see more

Sources

1

10

Debiopharm Group Acquisitions

4 Acquisitions

Debiopharm Group acquired 4 companies. Their latest acquisition was ImmunoGen - Antibody-Drug Conjugate on May 24, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/24/2017

$99M

Acquired Unit

1

8/30/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/14/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/11/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/24/2017

8/30/2016

7/14/2016

2/11/2014

Investment Stage

Series A

Series A

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired Unit

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

Debiopharm Group Partners & Customers

10 Partners and customers

Debiopharm Group has 10 strategic partners and customers. Debiopharm Group recently partnered with Aspen Pharmacare Holdings on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/1/2022

Licensee

South Africa

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

Lausanne , Switzerland and Durban , South Africa - Debiopharm , a Swiss biopharmaceutical company and Aspen Pharmacare , a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer .

1

6/18/2021

Partner

South Korea

1

6/16/2021

Partner

South Korea

Ubix Therapeutics, Debiopharm team up to develop new anticancer modality2021.06.16 16:10

Ubix Therapeutics , Debiopharm team up to develop new anticancer modality

2

3/8/2021

Licensee

United States

Subscribe to see more

Subscribe to see more

10

3/8/2021

Licensee

Germany

Subscribe to see more

Subscribe to see more

10

Date

2/1/2022

6/18/2021

6/16/2021

3/8/2021

3/8/2021

Type

Licensee

Partner

Partner

Licensee

Licensee

Business Partner

Country

South Africa

South Korea

South Korea

United States

Germany

News Snippet

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

Lausanne , Switzerland and Durban , South Africa - Debiopharm , a Swiss biopharmaceutical company and Aspen Pharmacare , a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate cancer .

Ubix Therapeutics, Debiopharm team up to develop new anticancer modality2021.06.16 16:10

Ubix Therapeutics , Debiopharm team up to develop new anticancer modality

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Debiopharm Group Team

6 Team Members

Debiopharm Group has 6 team members, including current Chief Executive Officer, Tanja Dowe.

Name

Work History

Title

Status

Tanja Dowe

Innomedica, BioSolutions, and Tekes

Chief Executive Officer

Current

Bertrand Ducrey

Chief Executive Officer

Current

Cedric Sager

Chief Executive Officer

Current

David Deperthes

President

Current

Thierry Mauvernay

President

Current

Name

Tanja Dowe

Bertrand Ducrey

Cedric Sager

David Deperthes

Thierry Mauvernay

Work History

Innomedica, BioSolutions, and Tekes

Title

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

President

President

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.